Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreren
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

APELLIS PHARMACEUTICALS, INC.

(APLS)
  Rapport
Vertraagde tijd Nasdaq  -  22:00:01 08-02-2023
52.29 USD   -4.84%
06/02Insider Sell: Apellis Pharmaceuticals
MT
25/01Insider Sell: Apellis Pharmaceuticals
MT
09/01Transcript : Apellis Pharmaceuticals, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 09:00 AM
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op APELLIS PHARMACEUTICALS, INC.
06/02Insider Sell: Apellis Pharmaceuticals
25/01Insider Sell: Apellis Pharmaceuticals
09/01Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635
06/01Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
06/01Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
05/01Apellis Pharmaceuticals, Inc. : Change in Directors or Principal Officers (form 8-K)
05/01Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
05/01Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
05/01Apellis Appoints Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
04/01North American Morning Briefing: Futures Rise -2-
03/01Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
03/01Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022Apellis Files Marketing Authorization Application With European Medicines Agency for Ex..
2022Apellis Submits Marketing Authorization Application to the European Medicines Agency fo..
2022Apellis Submits Marketing Authorization Application to the European Medicines Agency fo..
2022Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
2022Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
2022Insider Sell: Apellis Pharmaceuticals
2022Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2022Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 20..
2022Apellis Says FDA Accepts Amended New Drug Application for Eye Disease Drug Candidate; S..
2022Sector Update: Health Care Stocks Advance Pre-Bell Friday
2022Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 20..
2022Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 20..
2022North American Morning Briefing: Fed Hopes, China -3-
2022Insider Sell: Apellis Pharmaceuticals
2022Apellis Pharmaceuticals Q3 Loss Narrows, Revenue Rises
2022APELLIS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condit..
2022Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine M..
2022Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q3 Revenue $22.1M
2022Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results
2022Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results
2022Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635
2022Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
2022Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
2022Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profil..
2022Insider Sell: Apellis Pharmaceuticals
2022Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan ND..
2022Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan ND..
2022Apellis Pharmaceuticals, Inc. Announces Plans to Submit 24-Month Phase 3 Data to the FD..
2022Safety Of Intravitreal Pegcetacoplan : 24-month results from the OAKS and DERBY phase 3 tr..
2022Efficacy Of Intravitreal Pegcetacopl : 24-month results from the phase 3 OAKS and DERBY tr..
2022Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profil..
2022Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profil..
2022Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profil..
2022Apellis Pharmaceuticals to Host Conference Call on Nov 7 2022 to Discuss Third Quarter ..
2022Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter..
2022Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter..
2022Insider Sell: Apellis Pharmaceuticals
2022Apellis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
2022Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
2022Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
2022Insider Sell: Apellis Pharmaceuticals
2022Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studi..
2022Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacopla..
2022Safety Of Intravitreal Pegcetacoplan : 24-Month Results from the Phase 3 OAKS and DERBY Tr..
2022Efficacy Of Intravitreal Pegcetacopl : 24-Month Results from the Phase 3 OAKS and DERBY Tr..
2022Aao 2022 : Treatment of Geographic Atrophy Secondary to AMD with Pegcetacoplan: Two-Year O..
2022Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacopla..
2022Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacopla..
2022Apellis Pharmaceuticals, Inc. Announces 24-Month Phase 3 Post Hoc Results Showing Treat..
2022Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studi..
2022Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studi..
2022Insider Sell: Apellis Pharmaceuticals
2022Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global H..
2022Insider Sell: Apellis Pharmaceuticals
2022Insider Sell: Apellis Pharmaceuticals
2022Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
2022Insider Sell: Apellis Pharmaceuticals
2022Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2022Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2022Analyst recommendations: Nvidia, Thermo Fisher Scientific, Danah..
2022Apellis Pharmaceuticals : 24-month Phase 3 DERBY and OAKS results Presentation
2022Apellis Pharmaceuticals, Inc. : Other Events (form 8-K)
2022Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacopl..
2022Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacopl..
2022Apellis Pharmaceuticals, Inc. Announces 24-Month Results Showing Increased Effects Over..
2022Insider Sell: Apellis Pharmaceuticals
2022Insider Sell: Apellis Pharmaceuticals
2022Insider Sell: Apellis Pharmaceuticals
2022Apellis Pharmaceuticals Narrows Q2 Loss, Revenue Rises
2022Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q2 Revenue $16.3M
2022Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q2 Loss $-1.46
2022Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results
2022APELLIS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condit..
2022Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results
2022Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six M..
2022Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
2022Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
2022Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
2022Insider Sell: Apellis Pharmaceuticals
2022Apellis Pharmaceuticals, Inc. : Entry into a Material Definitive Agreement, Unregistered S..
2022Apellis Pharmaceuticals to Host Conference Call on Aug 8, 2022 to Discuss Second Quarte..
2022Apellis Pharmaceuticals to Host Conference Call on Aug 8, 2022 to Discuss Second Quarte..
2022Insider Sell: Apellis Pharmaceuticals
2022Apellis Pharmaceuticals Enters Agreements to Exchange $75.6 Million of Convertible Seni..
2022Apellis Pharmaceuticals : Announces Agreements to Exchange Approximately $75.6 Million in ..
2022Apellis Pharmaceuticals, Inc. : Entry into a Material Definitive Agreement, Unregistered S..
2022Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amoun..
2022Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amoun..
Volgende evenement op APELLIS PHARMACEUTICALS, INC.